Overview

Dr Cabral is the co-founder and current director of the young adult rheumatic disease (YARD) clinic with Mary Pack Arthritis Program of the Vancouver Coastal Health Authority. He has an interest in characterising the processes and difficulties that young adults have in transitioning from the child health care delivery system to the adult system. He is actively involved in clinical and translation research focused on the paediatric rheumatic diseases including chronic arthritis, systemic lupus erythematosus and vasculitis. He is participating in, and involved in the development of, national and international networks and patient registries to facilitate this research.

Research

Pediatric Osteoporosis
I am currently site principal investigator and on the steering committee of a CIHR funded national, multicentre observational study of steroid-induced osteoporosis in the paediatric population. This cohort of patients with acute lymphatic leukemia, nephrotic syndrome and rheumatic diseases is already the largest of its kind. The study will provide previously uncharacterised baseline characteristics and natural history of bone health in these populations. This will also establish a basis for collaborative intervention studies.

Systemic lupus erythematosus
As part of a recently funded "CIHR team in childhood autoimmunity" investigating the common underlying mechanisms and pathways in childhood onset systemic lupus erythematosus (SLE) and diabetes, I am clinical co-investigator for the SLE arm of this study.

Pediatric vasculitis
I have lead an initiative since 2004 in the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and established a network of Canadian and American CARRA-associated pediatric Rheumatology centers (more than 50 centers) to study a cohort of patients with the rare Pediatric chronic vasculitides using ‘Web-based’ data entry systems. The initial focus is on Wegener’s granulomatosis and other related small-medium vessel or ANCA-related vasculitidies and is described as A Registry of Childhood Vasculitis: e-entry. ARChiVe. Because of the rarity of these diseases there is limited opportunity to study the unique pediatric clinical features and outcomes with and without various treatments. The current cohort of nearly 50 patients is already double that of any previous study.

Chronic Arthritides of Childhood
A productive ad hoc research alliance of Western Canadian paediatric rheumatology centres (in which I was a coinvestigator) provided the model for a successful national endeavor of the Canadian Pediatric Rheumatology Association in obtaining a CIHR New Emerging Team (NET) Grant: New onset juvenile idiopathic arthritis: A Canadian multi-centre collaborative outcomes study (2004). Vancouver is a core site for this endeavour and Dr Lori Tucker is one of the co-investigators. The early success of this collaboration has also lead to the successful funding of a second grant: Biological based predictors of outcome in JIA: the BBOP study. Again, Vancouver is also a core center for basic research. Dr Stuart Turvey is a co-investigator. This five year program, unique in North America, has already enrolled nearly 500 children with new onset JIA as a cohort of for current and future studies of international significance. Currently, I am a member of the interim steering committee of this research network that has evolved and become known since 2006 as the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI).

Research Group Members

Felice Mizan, Research Coordinator
Angelyne Sarmiento, Research Manager